phd consultant adelaide

International Students

PhD and Masters Research Degrees In Australia

Are you looking to further your knowledge and become an expert in your field of interest? Start your greatest adventure with a Higher Degree by Research at the University of Adelaide.

Ranked in the top 100 of universities globally, at the University of Adelaide you will be involved in discovery, innovation and cutting-edge research. Enjoy an outstanding research environment under the wing of top-ranked researchers and establish life-long connections with industry and like-minded students. Start building your future now.

Find your degree

There is an option for every discipline. Explore our Masters and Doctorate degrees by research.

Industry opportunities

Turn theory into practice with a research internship and industry-engaged higher degree research program (HDR). Develop expertise in your chosen field and extend your professional contacts and networks.

Programs are open to applicants who are eligible for onshore study and meet the University of Adelaide’s English Language Requirements at the time of the application.

International joint PhDs

Widen your research connections and study at two high quality universities within Australia or between different countries.

You will spend time at each university and receive a single doctoral degree jointly awarded by both institutions.

Research connections

Australian Institute for Machine Learning

The University of Adelaide’s Australian Institute for Machine Learning is the largest university-based research group in machine learning in Australia. Research areas include agriculture, space, medicine, transport, defence, cybersecurity and advanced manufacturing.

The University of Adelaide is a founding member of SAHMRI, South Australia’s independent, not-for-profit health and medical research institute. Research areas include clinical trials, genetics, Aboriginal health, public health and medical imaging.

International scholarships

The University of Adelaide offers a range of strategic and merit-based scholarships for outstanding Higher Degree by Research applicants.

International student resources

Why study a research degree with us?

The infrastructure and supports for research students are excellent. I have enjoyed access to a range of services and courses created to promote career development. The staffs are friendly and very helpful.

Dr Withawat Withayachumnankul

Want to learn more?

About the university of adelaide.

Call us:  +61 8 8313 4455

(Toll free 1800 407 527)

More information

Make history.

Study at Adelaide

Postgraduate research degrees.

The time you dedicate to a PhD is an investment in yourself and your future. Accelerate your personal development, professional capabilities and career opportunities in ways no other experience can.

Apply for a PhD

We offer over 300 research degree projects across Health, STEM, Agriculture, Energy and many other study areas. 

Why Adelaide?

Top 100 Universities Worldwide

Home to over 110 rhodes scholars, group of eight australia.

Interested in making your own history and pursuing a PhD at the University of Adelaide? Check out what some of our current PhD candidates are achieving.

Getting your PhD brochure

Learn more about how and why to complete your doctorate at South Australia's global, research-intensive university. 

Scholarships

Choosing Adelaide?

Find out more about applying for a Postgraduate research degree.

Enquire now

Student support services, further enquiries.

Call us:  +61 8 8313 7335

Toll free:  1800 407 527

Study with us

Undergraduate Postgraduate International students Adult entry / non-school leaver

More information

Answers to your questions Study overseas Student finance Admissions information

Faculty of Sciences, Engineering and Technology

Higher Degrees by Research

Whether you intend to work in academia, government or industry, a higher degree by research can give you a competitive edge throughout your career.

With our research areas positioned above world standards * , and six disciplines ranked in the top 50 globally ^ , our internationally renowned academics are at the cutting edge of research and discovery.

By undertaking a research degree with us, you will be involved in discovery, innovation and cutting-edge research. Our strong focus on addressing global challenges creates a highly stimulating setting for our students interested in changing the world.

We provide a stimulating environment for research students. Be part of a thriving research culture which promotes excellence, fosters creativity and catalyses success.

Study options

Join our  Master of Philosophy  or  Doctor of Philosophy  research programs and experience specialised and research-intensive study.

Finding research opportunities

Research degrees in laboratories and groups at the University are highly competitive.

Finding a research project that drives your passion is a two-step process:

• You need to find an opportunity to work on a project that interests you, and then
• You will need to find a supervisor to work with.

Your highest chance of success will likely come from identifying areas that are a good ‘fit’ to your own research interests and your previous research experience.

If you find a lab or group that matches the criteria, contact them directly by email to introduce yourself. At this point, you should provide evidence of your academic achievements and, most importantly, details and evidence of your previous research training, such as scientific publications.

Found a research opportunity?

Once you have decided on a research project, an Academic will need to assess your eligibility.

Send the following to your  potential supervisor  or to one of our  Postgraduate Coordinators  for an initial assessment:

• academic transcripts
• completed  expression of interest form

Once you have emailed the above to your potential supervisor, you can apply for admission and scholarships through the Adelaide Graduate Research School. 

Admissions and scholarship applications

The  Adelaide Graduate Research School  administers applications for both admission and scholarships (domestic and international).

Scholarships

Scholarships for research degrees are available to international and domestic students. You can increase your chances of gaining a scholarship by having an established list of published research papers in internationally recognised peer-reviewed journals.

Domestic students   International students

Hear from us

Considering taking the next step and studying a Research Degree with us? Check out the recording of our recent info session to hear from a range of speakers what it’s like to undertake a research degree at UoA.

Industry engaged research

The University of Adelaide Industry PhD (UAiPhD) is an exceptional and innovative 4 year program, which includes a 6 month industry placement.

Gain valuable understanding about how organisations innovate and solve real world problems, making an impact with your research while gaining a significant employment advantage. 

Find out more

For more information, please contact the Adelaide Graduate Research School

• Email:  [email protected]
• Tel: +61 8 8313 5882
• Free Call: 1800 061 459

*  2018 Excellence in Research Australia ERA ^  Academic Ranking of World Universities 2020

Researcher Profiles

Professor Deborah White

Director, Cancer Program and Deputy Theme

Adelaide Medical School

Faculty of Health and Medical Sciences

Eligible to supervise Masters and PhD - email supervisor to discuss availability.

Professor Deborah White PhD FFSc (RCPA)

Professor White is the Director of the Cancer Program and Deputy Precision Medicine Theme Leader at the South Australian Health and Medical Research Institute (SAHMRI) in Adelaide. She is a NHMRC RD Wright Biomedical Research Fellow, a Beat Cancer Prinicpal Research Fellow and Senior Principal Research Fellow with SAHMRI. She is a Professor in Health and Medical Sciences at the University of Adelaide and Health Sciences at Uni SA.

Prof White’s research focus is genomics and rationally targeted therapies in Acute Lymphoblastic Leukaemia (ALL) and Chronic Myeloid Leukaemia (CML) and she holds peer reviewed grants from: The William Lawrence and Blanche Hughes Foundation and the Leukemia Lymphoma Society (USA), the NHMRC, the Leukaemia Foundation Australia (LFA), Channel 7, Cancer Australia, Tour de Cure and the Cancer Council SA (CCSA). Professor White has presented more than 170 papers at scientific meetings, and authored more than 100 scientific publications as well as being an inventor on several international patents.

Professor White is the National Flagship Lead for the ALL Stream of Australian Genomics, and SA scientific lead for Zero Children’s Cancer She is an active member of the National Health & Medical Research Council (NHMRC) being a member of the NHMRC Academy, the Translational Research Program Advisory Committee, and the Women in Health Science (WiHS) Committee. She is a member of the Editorial Board for Cancer Letters.

In 2014 she was recognised as the Australian Society for Medical Research (ASMR) Leading Light for her Medical Research and in 2016 was awarded the University of Adelaide James McWha medal. In 2019 she was awarded a prestigious NHMRC Research Excellence Award and awarded the Beat Cancer Women in Leadership Award in 2020.

• My Research
• Publications
• Grants and Funding
• Supervision
• Professional Activities

Leukaemia Research Group  -  Precision Medicine Theme, Cancer Program, SAHMRI

Lead: Professor Deborah White

Email: [email protected]  

A/ RESEARCH PROJECT Brief description of research area.

T-cell Acute Lymphoblastic Leukaemia (T-ALL) is a genomically complex, high-risk disease affecting both children and adults. Novel, targeted treatments are urgently required to prevent drug resistance and relapse. T-ALL is characterised by recurrent gene fusions and concomitant structural abnormalities. Ongoing advances in next generation sequencing (NGS) have enabled classification of a diverse range of genomic alterations resulting in new T-ALL subtypes. Critically, the wealth of genomic information available has identified new and recurrent genomic lesions but their biological and clinical implications remain unclear. Incorporating the knowledge gained through NGS into clinical care presents a major challenge. 

Currently, up to 30% of paediatric/adolescent T-ALL patients relapse with subsequent poor overall survival; the outcome is worse for adult patients with long-term survival rates after relapse below 10%. The over-arching focus of my studies is the generation of patient-derived xenograft (PDX) and transgenic mouse models of T-ALL from patient samples received in the laboratory. These models will be used to (1) examine re-purposing drugs and testing novel therapies; and (2) provide therapeutic options for pre-emptive intervention in the case of therapy-resistant disease. Central nervous system (CNS) involvement is common in relapsed ALL but drivers of this aggressive disease are poorly defined. This project will use imaging studies to track specific disease subtypes demonstrating CNS penetration.

Research Project 1 - Dr Laura Eadie

Title: Evaluation of leukaemic invasion and penetrancein mouse models of ALL.

Project description: 

Our laboratory is the National Referral Centre for genomic screening of ALL cases allowing identification of genomic alterations in a large number of patients.Establishment of PDX models from these patient samples is ongoing. Recent PDXs have resulted in leukaemic engraftment within the brain, indicative of CNS involvement and suggesting an aggressive disease. CNS penetration in ALL is a significant un-met clinical need, however, the pathogenesis of CNS disease, the underlying genomic determinants and the biology driving CNS penetration remain poorly understood and targeted therapies are limited.

Additional PDX models resulted in rapid detection of leukaemic cells within the blood, but not the bone marrow or brain, highlight the complexity of individual leukaemias and the need for real-time disease imaging and tracking. Fluorescently-tagged cells harvested from PDX models or transgenic cells harbouring genomic lesions of interest will be used to investigate CNS involvement. Cells isolated from leukaemic organs will be comprehensively characterised using molecular biology and NGS approaches. Surface receptor expression profiles of leukaemic cells will be examined to determine potential causes of invasion. Computational network biology analyses will be performed to define druggable pathways. Results from this project will inform on disease invasion and allow evaluation of treatment strategies for aggressive disease phenotypes in real-time.

Projects available for:  Mphil / PhD

Location:  SAHMRI

Research project start:  Semester 1 

Special requirements:  Police Clearance

Max Number of Students: 1

Category: Wet Lab

Research Area: Cancer Biology and Clinical Oncology

B/ RESEARCH PROJECT  Brief description of research area.

Acute Lymphoblastic Leukaemia (ALL) is the most common childhood cancer, and leading cause of non-traumatic death in children. For adolescents and young adults (AYA) with ALL the therapeutic outcomes are poor. Most older adults will die of their disease. The recent wealth of genomic information has seen the emergence of new lesions known to confer high-risk, and other recurrent fusions and gene deletions for which the biological and clinical implications remain unclear. Further, recent studies have implicated the human microbiome in ALL development, treatment response and life-long comorbidities. The major challenge is to incorporate knowledge gained through Next Generation Sequencing (NGS) into clinical care and to systematically identify  druggable targets and rational effective therapies to improve patient outcomes. To add to the complexity of therapeutic choice in ALL, immunotherapies (bi-specific T-cell engagers (BiTEs) and CAR-T cells), have shown efficacy in the relapsed/refractory setting, as a transplantation bridge. However, not all high-risk/relapsed ALL patients are eligible for immunotherapy, ~50% of patients experience severe hypersensitivity reactions and the long-term clinical sequelae remains unknown. Our laboratory is the National Referral Centre for genomic screening of ALL cases across all age groups, as such we sequence a large number of patients and have identified a significant number of alterations and novel gene fusions for investigation.

Research Project 2 – 

Title: Cloning acute lymphoblastic leukaemia fusion genes and variants, functional characterisation and therapeutic responses.

Recent advances in genomic profiling have defined B-cell Acute Lymphoblastic Leukeamia (B-ALL) as a heterogeneous disease with multiple subgroups characterised by distinct genetic alterations. Many genomic lesions in B-ALL are associated with alterations of cytokine receptors or their signaling pathway mediators, transcription factors or regulators of differentiation.Genomic lesions in ALL patients stratify with prognosis and using transcriptomic analysis, we have identified a number of poorly characterisedfusion genes and variants in patients.  This project aims to clone full-length fusion-genes and gene variants from patient material into mammalian expression plasmids.  This will allow  in vitro characterisation in cell line models of aberrant signalling pathways that drive disease and assess therapeutic responses. This project will involve a range of molecular biology and cloning techniques including primer design, PCR Sanger sequencing, bacterial work, tissue culture and flow cytometry.

Projects available for:  Third Year (Basic Science) / Honours 

Research project start:  Semester 1

Special requirements: Police Clearance

Research Project 3 – Dr Sue Heatley

Title: Investigation of resistance mechanisms to the bispecific T-cell engager (BiTE)  blinatumomab in relapsed acute lymphoblastic leukaemia.

Recently, a new compound of drug known as Bispecific T-cell engager (BiTE) has been approved for use in B-ALL by the Food and Drug Administration (FDA) and is currently undergoing clinical trials in Australia. Blinatumomab is a BiTE that enables an immunological response between the CD19 positive leukaemic cell and a cytotoxic CD3 positive T-cell. While the introduction of blinatumomab promises to be an exciting addition to the clinical arsenal, initial response rates in relapsed/refractory ALL have been ~43% and, as with other treatments, resistance is likely to occur. Immune evasion is a likely cause of resistance as well as loss of the CD19 target, leading to CD19 negative relapse and further investigation is warranted.

Relapsed patient samples that are identified as being treated with blinatumomab will be flow sorted by CD19 positivity. CD19 positive and CD19 negative populations will undergo mRNAseq to identify if a lineage switch has occurred and if the driving event is now present in the CD19 negative population. Differences in gene expression will also be interrogated.

Resistance will be modelled  in-vitro by subjecting fusion constructs to incrementally increasing doses of blinatumomab, enabling further examination of potential immune evasion pathways. 

Projects available for:  Honours / Mphil / PhD

Appointments

Awards and Achievements

Research Interests

Conference Papers

Conference Items

Peer Reviewed Research Funding

I have been successful in securing competitive research funding (Approx $30million).

International Competitive Schemes LLS (CML. 2009 and 2016) and the Hughes Foundation/USC Parker Institute (ALL 2015, 2016) NHMRC (2007 (CML),2009(CML), 2012(CML), 2012 (ALL), 2013(CML),and 2014(CML), Leukaemia Foundation of Australia (LFA) (2008 2012 (CML) and 2013 (ALL)), Cancer Council of SA (2011 (CML) and 2012 (ALL) and Channel 7 2015 (ALL). NHMRC TCR in genomics now (AGHA)(ALL $25 million). A significant outcome of the work of my group has been the successful translation into clinical practice. In excess of $5.5 million in Pharmaceutical funding over the last 10 years has been secured.

International Peer Reviewed Competitive Schemes

2016 Developing a bioassay-based algorithm for selecting frontline therapy in chronic myeloid leukemia Timothy Hughes, CIB:Deborah L White, Gerald Radich, David Yeung, Chung Kok and John Reynolds   $US600,000.00   2015 Identification of mechanisms of drug resistance in paediatric models of Ph-like ALL treated with targeted therapies CIB- Charles Mullighan $US450,000.00   2009 The role of OCT-1 Activity enhancers in improving the response of patients with low OCT-1 activity to Imatinib $US600,000.00   National Peer Reviewed Competitive Schemes (Other than NHMRC) 2019 Precision Medicine in Acute Lymphoblastic Leukaemia Laura Eadie $250,000.00 2019 Acute Lymphoblastic Leukaemia: Understanding the factors that determine response to new immune-based therapies. David Lynn and Gerraint Rogers $100,000.00 2019 Reducing the toxicity associated with agonistic antibody cancer immunotherapies by targeting the gut microbiota Steven Blake, David Lynn and $50,000.00 2019 Precision Medicine in Acute Lymphobastic Leukaemia $600,000.00  2018 INFRASTRUCTURE: Australian Cancer Research Foundation Centre for Integrated Cancer Systems Biology (ACRFCICSB) CIs: Hughes, Zannettino, White, Proud, Wesselingh, Lynn, Butler, Gronthos, Tilley, Price, Worthley, Bulone $2,500,000.00  2018 INFRASTRUCTURE: A Bioinformatician for the Joint SAHMRI/AHMRI Bioinformatics Core $234,000.00  2018 The role of the gut microbiota in the efficacy and toxicity of agonistic antibody cancer immunotherapies Lynn D., Blake S. & White D $22,890.00  2017 Improving outcomes for high risk ALL treated with new therapies and transplant. Rosemary Sutton, Deborah White, Toby Trahair, Peter Shaw  $600,000.00  2017 Rapid Identification of High Risk Subtypes & Targeted Treatments for Children with Acute Lymphoblastic Leukaemia Toby Trahair, Rosemary Sutton, Glenn Marshall, Draga Barbaric, Luciano Dalla Pozza, Deborah White $200,000.00  2017 INFRASTRUCTURE: Adelaide Flow Cytometry Facility. Robertson, McColl, Zannettino, Tyreman, Thompson, Mitchell, Brown, McKinnon, Hayball, Cowin, Makridis, White $480,000.00  2017 INFRASTRUCTURE: Zero Childhood Cancer $20,000,000.00 (Received $1,479,303.00) 2017 Better Outcomes for Child & Adolescent ALL Project. Toby Trahair, Marion Mateos, Glenn Marshall, David Ziegler, Rosemary Sutton, Rishi Kotecha, Siobhan Cross, Deborah White $200,000.00 2016 Improving outcomes for children with leukaemia through molecular targeted therapies $800,000.00  2016 High-Risk T cell ALL Laura Eadie and Deborah White $75,000.00 2016 Single cell genomics in high-risk ALL Susan Heatley and Deborah White  $176,000.00  2016 INFRASTRUCTURE: Transforming research into improved heatlh for patients with Leukaemia $90,000.00 2015 Developing a robust screening tool to identify children with high risk “Ph-like” Acute Lymphoblastic Leukaemia (ALL) that will lead to improved outcomes through the use of targeted therapies Susan Heatley, Deborah White, Charles Mullighan $75,000.00 2013 INFRASTRUCTURE: Cancer Imaging and Therapeutics Facility CIs: Mullighan, Hughes, White, Zannettino, Gronthos, Keefe, Monro, Roder, Tilley, Price. $1,800,000.00  2013 Childhood Ph-like ALL: Improving Diagnostic Screening and Therapeutic Rationale $100,000.00  2012 INFRASTRUCTURE: Establishing the SA Biospecimen Respository $980,000.00  2012 Assessing the cause and drug susceptibility of Adult high-risk ALL $80,000.00  2012 Characterisation of immune responses in CML patients on nilotinib and interferon alpha Yong, A, Hughes, T and White DL $100,000.00  2012 Developing a gene signature to predict the optimal front line kinase inhibitor for CP-CML patients $99,254.00  2011 Developing a patient specific approach to the treatment of CP-CML with tyrosine kinase inhibitors: investigating the factors which determine response to nilotinib and dasatinib $92,508.00  NHMRC Schemes (peer reviewed) (>$13 million) 2019 Setting a new Paradigm for Diagnosis and Therapeutic Triage in ALL using Functional Genomics $483,404.00  2017  Chronic myeloid leukaemia: changing the treatment paradigm CI’s: Hughes, Ross, Branford, White, Yong, and Reynolds $1,162,778.08 2016 Genomics Translation: Preparing Australia for Genomic Medicine: A Proposal by the Australian Genomics Health Alliance (AGHA) $25,000,000.00 (Received $1,250,000.00) 2015 Aberrant Signalling in Leukaemia CI’s: A. Lopez, T Hughes, M Parket AI: White, D $6,669,345.00 2014 Determining the prerequisites for the achievement of treatment-free remission in chronic myeloid leukaemia to facilitate the development of new therapeutic approaches with curative intent CIA: Timothy Hughes, CIB: Deborah White, CIC: Susan Branford, CID:David Ross, CIE:Agnes Yong $1,400,000.00  2013 Screening and targeting newly discovered genetic lesions in poor risk adult and childhood ALL $718,892.85  2012 Characterisation of a New Poor-Risk Sub-Category of Chronic Phase Chronic Myeloid Leukaemia $588,675.00  2012 Rational development of a bioassay-based treatment algorithm for kinase inhibitor therapy in CML CIA Timothy Hughes, CIB Deborah White, CIC John Rasko $509,880.00  2009 Development and assessment of novel assays to predict response to second-line TKI therapy in imatinib resistant CML CIA:Timothy Hughes, CIB: Junia Melo, CIC:Susan Branford, CID: Deborah L White $485,000.00 Industry Funding - Granted (>$5.5 million) 2015 Correlative Science Proposal Associated with the DIRECT study $598,000.00  2015 Correlative Science Proposal Associated with the REGALLIA Clinical Registry $902,965.00  2015 Correlative Science Proposal Associated with the LENI David Ross, Timothy Hughes, Deborah Whiteand Agnes Yong $440,000.00  2014 Correlative Science Proposal Associated with the ENESTswift clinical trial $500,000.00  2014 Correlative Science Proposal Associated with the PINNACLE clinical trial $675,000.00  2012 Correlative Science Proposal Associated with the ALL06 clinical trial $94,560.00  2011 Provision of imatinib OCT-1 Activity testing for newly diagnosed CML patients $155,925.00  2011 Correlative Science Proposal Associated with the ENESTxtnd clinical trial $698,255.68  2011 Correlative Science Associated with TIDELII Clinical Trial - expansion of patient numbers $65,971.00  2011 Seed Funding: Investigating the Prevalence of Druggable Novel Gene Fusion, Detectable by Phospho-Flow Analysis in High Risk Adult B-ALL $20,880.00  2010 RESIST Registry Timothy Hughes and Deborah White $920,000.00  2010 Correlative Science Associated with TIDELII Clinical Trial Cohort 2 $659,707.91  2009 Correlative Science Proposal Associated with the Ph+ ALL- Dasatinib clinical trial. $154,919.00  Local Schemes- Granted 2017 Evaluate role of cellular influx and efflux pumps in Azacitidine Devendra Hiwase, Sophie Watts, Verity Saunders, Timothy Hughes, Deborah White and Amilia Wee $25,000.00  2017 Functional effects of mitochondrial mutations in CML David Ross and Deborah White, Ilaria Pagani and Timothy Hughes $25,000.00  2016 Do mitochondrial mutations in chronic myeloid leukaemia identify a pre-leukaemic clone David Ross and Deborah White $25,000.00 2016 Identification of mechanisms of drug resistance in models of Ph-like ALL treated with targeted therapies David Yeung, Sue Heatley, Tessa Sadras, Tim Hughes, Deborah White $25,000.00 2015 Digital PCR for BCR-ABL DNA in chronic myeloid leukaemia David Ross and Deborah White $30,000.00 2014 Mitochondrial mutations in chronic myeloid leukaemia. David Ross and Deborah White $30,000.00 Undergraduate Lectures Guest Lecturer CML Biology 3 rd Year Health and Biotech, University of SA Guest Lecturer 3 rd Year Pharmacology Guest Lecturer 3 rd Year Biomedical Science  Guest lecture series Final Year Advanced Biomedical Science + associated tutorials Project Mentor to third year MBBS students; Research Project Design: ALL Current Higher Degree by Research Supervision (University of Adelaide) Date Role Research Topic Program Degree Type Student Load Student Name 2024 Principal Supervisor Clinical Transcriptomic Sequencing Analysis Workflows for Acute Lymphoblastic Leukaemia (ALL): Improving Subtype Characterisation in Complex Fusion Events Doctor of Philosophy Doctorate Full Time 2024 Principal Supervisor Identifying Predictors of CNS involvement in Acute Lymphoblastic Leukaemia Doctor of Philosophy Doctorate Full Time Mr Luke Jacob Quinlan 2023 Co-Supervisor Modelling co-occurring mutations in T-cell Acute Lymphoblastic Leukaemia to enhance treatment options and maximise the power of next generation sequencing Doctor of Philosophy Doctorate Full Time 2023 Co-Supervisor Discovery of novel metabolic targets against lDH1-mutant intrahepatic cholangiocarcinoma Doctor of Philosophy Doctorate Full Time Mrs Tasnova Tasnim Nova 2023 Principal Supervisor Interrogating the DUX4 rearranged subtype of B cell Acute Lymphoblastic Leukaemia Doctor of Philosophy Doctorate Full Time Mr Thomas Oliver McGovern 2023 Principal Supervisor Exploring the impact of the gut microbiota on the clinical scenario in Acute Lymphoblastic Leukaemia patients Doctor of Philosophy Doctorate Full Time 2022 Principal Supervisor Characterisation of a novel fusion, genetic contributors and effectiveness of drug combinations in Ph-like Acute Lymphoblastic Leukaemia and the clinical relevance. Doctor of Philosophy Doctorate Full Time Jane Frances Thompson 2022 Co-Supervisor A humanized monocyte model of TET2 mutated clonal hematopoiesis for noel target discovery Doctor of Philosophy Doctorate Full Time Miss Maha Kamel 2021 Principal Supervisor Investigation of current, innovative treatments and the roles of secondary genomic lesions in BCR-ABL1 positive leukaemias Doctor of Philosophy Doctorate Full Time Mr Elias Lagonik Past Higher Degree by Research Supervision (University of Adelaide) Date Role Research Topic Program Degree Type Student Load Student Name 2019 - 2023 Co-Supervisor Bioinformatic approaches to variant detection and subtype classification in acute lymphoblastic leukaemia Doctor of Philosophy Doctorate Full Time Miss Jacqueline Ann Rehn 2019 - 2022 Principal Supervisor Characterising KMT2A and MLLT10 Rearranged Acute Lymphoblastic Leukaemia Doctor of Philosophy Doctorate Full Time Miss Michelle Olivia Forgione 2018 - 2022 Principal Supervisor Precision Medicine Approaches for JAK2-Rearranged Acute Lymphoblastic Leukaemia: The Efficacy of Targeted Therapies and Molecular Mechanisms of Drug Resistance Doctor of Philosophy Doctorate Full Time Miss Charlotte Emma-Jeane Downes 2018 - 2021 Principal Supervisor Exploring the cooperation and targetability of CRLF2 and HMGN1 in Down Syndrome Acute Lymphoblastic Leukaemia Doctor of Philosophy Doctorate Full Time 2017 - 2021 Principal Supervisor Characterising the novel MYB-TYK2 fusion gene in high-risk acute lymphoblastic leukaemia: oncogenic potential, effective therapeutic strategies and In vitro modelling of drug resistance mechanisms Doctor of Philosophy Doctorate Full Time Miss Paniz Tavakoli Shirazi 2016 - 2021 Principal Supervisor The Combined Treatment Efficacy of Anti-CD123 CAR T cells with Azacitidine for the Treatment of Acute Myeloid Leukaemia. Doctor of Philosophy under a Jointly-awarded Degree Agreement with Doctorate Full Time Miss Nadia El-Khawanky 2015 - 2019 Principal Supervisor Multiple Molecular Mechanisms Contribute Towards In Vitro Resistance to Tyrosine Kinase Inhibitors In Chronic Myeloid Leukaemia Doctor of Philosophy Doctorate Full Time Mr Benjamin Chia Sing Leow 2014 - 2018 Principal Supervisor In vitro Modelling of High-risk ALL Fusions Uncovers Genomic Alterations and Non-canonical Signalling Pathways as a Mode of TKI-Resistance - Implications for Targeted Therapy Doctor of Philosophy Doctorate Full Time Miss Kartini Asari 2012 - 2014 Co-Supervisor The role of cytokines in governing the expansion of the T315I mutation in Chronic myeloid leukaemia Master of Philosophy (Medical Science) Master Full Time Dr Oi-Lin Lee 2012 - 2016 Principal Supervisor In Vitro Investigation of Intracellular Ponatinib Transport and Modeling Ponatinib Resistence in BCR-ABL1+ Cell Lines: Implications for Therapeutic Strategies Doctor of Philosophy Doctorate Full Time Miss Liu Lu 2012 - 2018 Co-Supervisor Personalized Medicine Support System for Chronic Myeloid Leukaemia Patients Doctor of Philosophy Doctorate Full Time Mrs Haneen Reda M Banjar 2010 - 2014 Co-Supervisor Assessment of Critical Survival Mechanisms Exploited by BCR-ABL1+ Cells to Evade Tyrosine Kinase Inhibitor-Induced Death; Determination of Novel Therapeutic Targets in Chronic Myeloid Leukaemia Doctor of Philosophy Doctorate Full Time Miss Lisa Schafranek 2010 - 2014 Principal Supervisor Defining CP-CML patient subsets associated with poor imatinib uptake and response Doctor of Philosophy Doctorate Full Time Mr Dale Benjamin Watkins 2009 - 2013 Co-Supervisor Nilotinib Efflux and Resistance Development: The Effects of Combination and Concomitant Therapies on the Transport and Efficacy of Nilotinib Doctor of Philosophy Doctorate Full Time 2008 - 2013 Co-Supervisor Investigating Drugs that Enhance Imatinib Uptake and Factors which Contribute to the Functional Activity of OCT-1 in CML Cells Doctor of Philosophy Doctorate Full Time Miss Jueqiong Wang 2008 - 2010 Co-Supervisor Evaluation of Anti-proliferative and Pro-apoptotic Effects of Tyrosine Kinase Inhibitors on CML-CD34+ Cells Doctor of Philosophy Doctorate Full Time APrf Devendra Hiwase 2008 - 2011 Co-Supervisor Cell Lineage, Cell Maturity and BCR-ABL: Factors Which Influence Imatinib Uptake in Chronic Myeloid Leukaemia Doctor of Philosophy Doctorate Full Time Ms Jane Engler 2008 - 2012 Co-Supervisor TKI Resistance in CML Cell Lines: Investigating Resistance Pathways Doctor of Philosophy Doctorate Full Time Mrs Carine Tang Board Memberships Date Role Board name Institution name Country 2023 - ongoing Member South Australian Genomics Consortium (SAGC) Advisory Board SAGC Australia 2023 - ongoing Director Board of Directors Australian and New Zealand Children's Oncology Group (ANZCHOG) ANZCHOG Australia 2023 - ongoing Director Board of Directors Australasian Leukaemia Lymphomas Group (ALLG) ALLG Australia 2016 - ongoing Member Nuclear Fuel Cycle Royal Commission Consultation and Response Advisory (CARA) Board - - Committee Memberships Date Role Committee Institution Country 2017 - ongoing Advisory Board Member Australian and New Zealand Children's Hematology/ Oncology Group Australia 2016 - ongoing Member Scientific Symposium Committee South Australian Health and Medical Research Institutesa Australia 2016 - ongoing Founder Statewide Cancer Translational Research Group - Australia 2016 - ongoing Founder SA Translational Cancer Research Group Meetings - Australia 2016 - ongoing Chair Post Graduate Student Forum Basil Hetzel Institute Research Day Australia 2016 - ongoing Chair SAHMRI Imaging Workshop South Australia Health and Medical Research Institute - 2016 - ongoing Chair Women in Health Science Session National Directions in Leukemia Research Australia 2016 - ongoing Chair ALL Stream of Australian Genomics Health Care Alliance (AGHA) - - 2016 - ongoing Member Scientific Committee for the New Directions in Leukaemia Research Conference - - 2016 - ongoing Member Australian Genomics Health Care Alliance (AHGA) Executive - - 2016 - ongoing Chair ALL Stream of the Australian Genomics Health Care Alliance (AHGA) - - 2016 - ongoing Chair SAHMRI Genomics Executive Committee - - 2015 - ongoing Member Women in Science Executive Committee - - 2015 - ongoing Member NHMRC Women in Health Science Faculty - - 2015 - ongoing Member National Women in Health Science Faculty NHMRC Australia 2015 - ongoing Chair Ross Wishart Memorial Award Australian Society for Medical Research Australia 2015 - ongoing Chair CML and Myelproliferative Neoplasms HAA - 2015 - ongoing Member US Ambassadors Round Table on Scientific Innovation - - 2015 - ongoing Member American Association for Cancer Research United States 2014 - ongoing Member International Chronic Myeloid Leukemia Foundation (iCMLf) Australia 2014 - ongoing Member Scientific Committee for the New Directions in Leukaemia Research Conference - - 2014 - ongoing Member SA Translational Haematology Research Group Meetings - - 2014 - ongoing Chair CML and Myeloproliferative Neoplasm Session New Directions in Leukemia Research Australia 2014 - ongoing Chair Women in Science session New Directions in Leukemia Research Australia 2014 - ongoing Chair Women in Science session New Directions in Leukemia Research Australia 2014 - ongoing Chair Young Investigator session New Directions in Leukemia Research Australia 2014 - 2016 Member SAHMRI post graduate student Committee - - 2014 - 2015 Advisory Board Member (Malignant Haematology) HAA Organising Committee - Australia 2013 - ongoing Member Biosciences Pillar Committee - - 2013 - ongoing Member Executive Management Committee - - 2013 - ongoing Member Research Executive Committee - - 2013 - ongoing Member BMS Advisory Board on Molecular Monitoring and Drug level Testing - - 2013 - 2015 Founder Haematology Statewide Translational Research Group - - 2013 - ongoing Member International Children's Oncology Group - 2012 - ongoing Member New Directions in Leukemia Research Conference - - 2012 - ongoing Chair Myeloid Leukaemia Session New Directions in Leukemia Research Australia 2012 - ongoing Chair Leukaemia Foundation Early Career Scientists Session New Directions in Leukemia Research - 2012 - ongoing Chair Bioscience Pillar SA Comprehensive Cancer Consortium (SACCC) - - 2012 - ongoing Member NHMRC Research Translational faculty - - 2012 - ongoing Member SAHMRI Bioscience Pillar Committee - - 2012 - ongoing Chair ALL Stream of the Australian Genomics Health Care Alliance (AHGA) - Australia 2012 - ongoing Member Research Translational faculty NHMRC Australia 2012 - ongoing Member Bioscience Pillar Committee South Australian Health and Medical Research Institute Australia 2012 - ongoing Member • Member of the South Australian Cancer Collaborative (SACCC) Executive Committee - - 2008 - ongoing Member Global Advisory Board Blood Level Testing and Mutational Analysis Novartis - 2008 - ongoing Member European Haematology Association - - 2008 - ongoing Member American Society of Haematology - United States 2008 - ongoing Member Haematology Association of Australia and New Zealand - Australia 2008 - ongoing Member Australian Leukemia and Lymphoma Group Australia 2000 - ongoing Member The Australasian Leukaemia & Lymphoma Group Scientific Committee - - Memberships Date Role Membership Country 2016 - ongoing Member Franklin Women - 2015 - ongoing Member American Association for Cancer Research - 2014 - ongoing Member International CML Foundation - 2013 - ongoing Member International Children’s Oncology Group (COG) - 2010 - ongoing Member Australian Leukaemia and Lymphoma Group: Laboratory Scientific Committee (only non-­clinician invited) - 2008 - ongoing Member Haematology Association of Australia and New Zealand - 2008 - ongoing Member Australian Leukaemia and Lymphoma Group (ALLG) - 2008 - ongoing Member European Haematology Association - 2008 - ongoing Member American Society of Haematology - Consulting/Advisories Date Institution Department Organisation Type Country 2016 - ongoing Department of Premier and Cabinet DPC and CARA Legislative and political Australia 2015 - ongoing Sigma Aldrich: Science Next Collaborative - - - 2013 - ongoing BMS Advisory Board on Molecular Monitoring and Drug level Testing - - - 2008 - ongoing Novartis Global Advisory Board Blood Level Testing and Mutational Analysis - - - Editorial Boards Date Role Editorial Board Name Institution Country 2016 - ongoing Associate Editor Journal of Blood Research & Hematologic Diseases - Position: Director, Cancer Program and Deputy Theme Phone: 0881284302 Email: [email protected] Campus: North Terrace Building: SAHMRI, floor 5 Org Unit: Adelaide Medical School Connect With Me External Profiles Other Links Adelaide Business School Higher Degrees By Research The Adelaide Business School offers research degrees at both the masters and doctorate levels: the Master of Philosophy (MPhil) and the Doctor of Philosophy (PhD).  Our programs are benchmarked with other Go8 universities, and our international collaborations in research (UNESCO and OECD reports, TIMSS and PISA studies) introduce broader issues into our theory and practice of education. If you are interested in accounting, finance and banking, management, marketing or entrepreneurship, then consider furthering your research career with us. Find a supervisor   Explore scholarships Join a community of innovative thinkers taking the lead with their high-quality, industry relevant research. Experience the mentorship of our internationally recognised academic supervisors. Associate Professor in Management Chad Chiu explains how your PhD can make an impact on society. Undertake cutting-edge research and connect with global industry partners. Associate Professor in Finance and Banking Jean Canil explains how there’s never been a better time, or place, to start your PhD journey. Make a meaningful impact on society as you explore your passion and create new knowledge. Our supportive and welcoming networks will set you up for the future. Janin Hetzen "I came across a scholarship opportunity at the University of Adelaide, I knew I had to apply. The fact that I am writing this here shows that I did get rewarded for 'going for it'. The scholarship was the first and probably most important reason as to why I chose to study at the University of Adelaide. I found great supervisors who shared my research vision and excitement -  they supported me in my decisions and guided me." Janin Hetzen, Master of Philosophy (Marketing) -  focused on mobile apps and getting young Australians more engaged with their Superannuation. Institute for International Trade Higher Degree Research Higher Degree Research in the IIT encompasses a diverse range of topics and disciplines, including basic and applied research addressing contemporary trade issues and informing trade policy discussions. IIT offers a research degree: Doctorate of Philosophy (PhD). PhD students from a variety of disciplines, including trade, development studies, economics, business and law, have studied for higher degrees within the IIT. Here they have played a critical role in the development of our rich multidisciplinary research environment. Browse Research Programs Your application We're here to help. If you have any questions about Higher Degree by Research studies, get in touch with us for further information. Learn more about admission 435 IMAGES Jill LIPSETT Dr Sara MCLEAN Adelaide Research Degrees Stephanus MALHERBE PhD Scholarships Approach Education Consultants for a PhD Study Program in Australia COMMENTS Doctor of Philosophy | Degree Finder - The University of Adelaide Doctor of Philosophy. The Doctor of Philosophy is the University’s flagship research award and is the standard pre-requisite for a career in research or academia. The PhD involves three – four years of research for a full-time candidate or the equivalent in half-time candidature. Dr Michael Collins | Researcher Profiles - University of Adelaide Dr Michael G. Collins MBChB FRACP PhD is a consultant nephrologist (kidney specialist) and clinical trialist working at the Royal Adelaide Hospital. He trained in Nephrology at Auckland City Hospital, New Zealand, and the Queen Elizabeth and Royal Adelaide Hospitals in Adelaide. PhD and Masters Research Degrees In Australia Are you looking to further your knowledge and become an expert in your field of interest? Start your greatest adventure with a Higher Degree by Research at University of Adelaide. Find out more about PhD's, masters degree programs and industry research opportunities. Postgraduate Research Degrees - The University of Adelaide Apply for a PhD. We offer over 300 research degree projects across Health, STEM, Agriculture, Energy and many other study areas. How to apply. Explore a research project. Why Adelaide? Higher Degrees by Research - University of Adelaide The University of Adelaide Industry PhD (UAiPhD) is an exceptional and innovative 4 year program, which includes a 6 month industry placement. Gain valuable understanding about how organisations innovate and solve real world problems, making an impact with your research while gaining a significant employment advantage. Michelle Thomas - Adelaide Private Surgeons Dr Michelle Thomas. (FRACS, CSSANZ, PhD) Michelle Thomas is a Consultant Colorectal Surgeon. She is a graduate of Monash University and undertook her surgical training in South Australia, Darwin and Bath, UK, becoming a fellow of the Royal Australian College of Surgeons in 2002. Dr Brendan Scott | Researcher Profiles - University of Adelaide Faculty of Sciences, Engineering and Technology. Eligible to supervise Masters and PhD - email supervisor to discuss availability. Lecturer in Geotechnical Engineering at the School of Civil, Environmental and Mining Engineering at the University of Adelaide. Professor Deborah White | Researcher Profiles Professor White is the Director of the Cancer Program and Deputy Precision Medicine Theme Leader at the South Australian Health and Medical Research Institute (SAHMRI) in Adelaide. She is a NHMRC RD Wright Biomedical Research Fellow, a Beat Cancer Prinicpal Research Fellow and Senior Principal Research Fellow with SAHMRI. Higher Degrees By Research | Adelaide Business School ... The Adelaide Business School offers research degrees at both the masters and doctorate levels: the Master of Philosophy (MPhil) and the Doctor of Philosophy (PhD). Our programs are benchmarked with other Go8 universities, and our international collaborations in research (UNESCO and OECD reports, TIMSS and PISA studies) introduce broader issues ... Higher Degree Research - University of Adelaide IIT offers a research degree: Doctorate of Philosophy (PhD). PhD students from a variety of disciplines, including trade, development studies, economics, business and law, have studied for higher degrees within the IIT. essay homework paper phd project resume review speech thesis